Utah Medical Products Inc (UTMD) · Oct 22, 2026 · Earnings
Miss — FY sales outlook near -7% versus prior roughly flat expectation
Utah Medical Products’ earnings show higher Q3 EPS, but revenue fell 12% and replacement growth remains behind plan as 2026 guidance deteriorates.
UTMD is trying to replace lost PendoTECH and China-distributor volume with new biopharma OEM customers, a replacement China distributor and its Orion acquisition; earlier 2026 planning assumed those efforts could keep sales roughly flat. This quarter shows the recovery is arriving too slowly.
The headline earnings improvement is mostly a cost-and-tax comparison, not renewed demand. Q3 revenue fell 12.1% to $8.621 million while EPS rose 6.8% to $0.876; the nine-month picture is weaker, with revenue down 12.2%, operating income down 10.6%, net income down 7.4%, and EPS down 5.3% (Income Statement).
| Measure | 3Q 2026 | 3Q 2025 | Change | 9M 2026 | 9M 2025 | Change |
|---|---|---|---|---|---|---|
| Net sales | $8.621M | $9.812M | -12.1% | $25.873M | $29.475M | -12.2% |
| Operating income | $2.795M | $2.611M | +7.0% | $8.009M | $8.961M | -10.6% |
| Net income | $2.787M | $2.631M | +5.9% | $8.077M | $8.720M | -7.4% |
| Diluted EPS | $0.876 | $0.820 | +6.8% | $2.537 | $2.680 | -5.3% |
| Gross margin | 56.1% | 57.1% | -1.0 pts | 57.5% | 56.8% | +0.7 pts |
The revenue hole is broader than the lost customers alone. The former PendoTECH and China distributor accounts, net of replacement sales, explain 52% of the nine-month sales decline, but Filshie sales also fell 15.7% year to date and NICU sales fell 17.7% (Revenue discussion). Orion added $619,000 of Q3 sales, but that acquisition mostly offsets weakness elsewhere rather than proving the core recovery is back on track.
Margins held up because expenses fell faster than gross profit, not because the operating engine accelerated. Q3 operating income benefited from much lower litigation and Femcare amortization costs; combined litigation and intangible-asset amortization expense fell to $228,000 from $920,000 a year earlier (Overview of Results). The nine-month adjusted EBITDA margin nevertheless declined to 43.7% from 45.8% (EBITDA discussion), indicating weaker underlying earnings power despite the cleaner expense base.
The key expectation reset is in sales, not Q3 EPS. Management now projects a 2026 consolidated sales decline close to 7%, whereas the prior standing plan aimed to offset the lost accounts and keep sales about level. New biopharma growth is explicitly slower than expected, although Q4 comparisons should become easier because the lost customers had little fourth-quarter revenue last year.
The balance sheet gives UTMD time to execute, but does not repair the demand problem. Cash and investments remained $85.2 million after dividends, buybacks, capital spending and the $5.0 million Orion purchase, with no debt (Balance Sheet). That financial resilience supports further investment, but the business still needs replacement revenue to scale faster and Filshie and NICU declines to stabilize.
Bottom line: This is a weak operating update dressed up by lower one-time costs, tax benefits and fewer shares. The company remains financially sturdy, but the central replacement-growth thesis has slipped from a roughly flat-sales recovery to another year of contraction.
10-Q revenue segmentation disclosure, November 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!